Advertisement

Off-pump coronary artery bypass for a heparin-allergic patient

  • Hirofumi Ide
  • Tatsuo Fujiki
  • Masaya Sato
  • Hidehito Endo
  • Kentarou Imamura
  • Ken-ichi Sudo
Article

Abstract

A 46-year-old man with no history of drug allergy developed acute myocardial infarction. Coronary angiographic findings revealed triple vessel disease. Serum hepatic enzymes were elevated due to heparin administered to control infarction, and an allergic reaction developed exclusively due to heparin. To avoid heparin use, we adopted heparin-free off-pump coronary artery bypass grafting through median sternotomy. The systemic anticoagulant agent argatroban was administered to maintain active clotting time over 200 seconds. The left internal thoracic artery was anastomosed to the left anterior descending artery, the radial artery to the diagonal branch, and the right gastroepiploic artery to the right coronary artery. Patency was confirmed by postoperative coronary angiography. No complications were noted. For patients with heparin allergy, off-pump coronary artery bypass grafting is a useful maneuver, because it can be conducted using anticoagulant agents other than heparin.

Key words

off-pump CABG heparin allergy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Okamoto S, Hijikata A. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. the importance of stereostructure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981; 101: 440–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Sugawara H, Kumon K, Tanaka K, Egou Y, Naitou T, Fujita T. Evaluation of a synthetic inhibitor MD805 as anticoagulant after open heart and vascular surgery. Kyobugeka 1983; 36: 533–37.Google Scholar
  3. 3.
    Fujii H, Kurasako N, Takebayashi T, Tanaka T, Sakano S, Kosogabe Y, et al. Argatroban, a selective thrombin inhibitor for anticoagulant therapy during and following vascular surgery. Masui 1996; 45: 1289–92.Google Scholar
  4. 4.
    Endo S, Kawada T, Mieda T, Hozon M, Abe T, Kikuchi T, et al. A clinical study of an antithrombin agent, argatroban for the prevention of platelet loss in left heart bypass with the Bio-medicus centrifugal pump. Jpn J Artif Organs 1995; 24: 513–6.Google Scholar
  5. 5.
    Cartier R, Blain R. Off-pump revascularization of the circumflex artery: technical aspect and short-term results. Ann Thorac Surg 1999; 68: 94–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Buffolo E, Silva de Andrade JC, Branco JN, Teles CA, Aguiar LF, Gomes WJ. Coronary artery bypass grafting without cardiopulmonary bypass. Ann Thorac Surg 1996; 61: 61–6.Google Scholar
  7. 7.
    Pfister AJ, Zaki MS, Mispireta LA, Corso PJ, Qazi AG, Boyce SW, et al. Coronary artery bypass without cardiopulmonary bypass. Ann Thorac Surg 1992; 54: 1085–92.PubMedCrossRefGoogle Scholar
  8. 8.
    Gundry SR, Romano MA, Shattuck OH, Razzouk AJ, Bailey LL. Seven-year follow-up of coronary bypasses performed with and without cardiopulmonary bypass. J Thorac Cardiovasc Surg 1998; 118: 12–8.Google Scholar
  9. 9.
    Messmore HL. Clinical efficacy of heparin fractions: issues and answers. Crit Rev Clin Lab Sci 23 1986; 23: 77–94.PubMedCrossRefGoogle Scholar
  10. 10.
    Nagasawa H, Fukutake K, Hada M, Takahashi E, Matsubara Y, Samori T, et al. Phase 1 study of synthetic antithrombin agent (MD-805). Single and multiple administration studies. Rinshobyouri 1981; 12: 359–75.Google Scholar

Copyright information

© Japanese Association for Thoracic Surgery 2001

Authors and Affiliations

  • Hirofumi Ide
    • 1
  • Tatsuo Fujiki
    • 1
  • Masaya Sato
    • 1
  • Hidehito Endo
    • 1
  • Kentarou Imamura
    • 1
  • Ken-ichi Sudo
    • 1
  1. 1.Department of Cardiovascular SurgeryKyorin Medical SchoolMitaka, TokyoJapan

Personalised recommendations